S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
NASDAQ:TWST

Twist Bioscience - TWST Stock Forecast, Price & News

$16.18
+0.20 (+1.25%)
(As of 03/24/2023 05:19 PM ET)
Add
Compare
Today's Range
$15.53
▼
$16.40
50-Day Range
$15.78
▼
$30.90
52-Week Range
$14.98
▼
$58.76
Volume
955,572 shs
Average Volume
1.23 million shs
Market Capitalization
$919.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.83

Twist Bioscience MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
109.1% Upside
$33.83 Price Target
Short Interest
Bearish
17.61% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.42
Upright™ Environmental Score
News Sentiment
0.30mentions of Twist Bioscience in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.89) to ($3.67) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

692nd out of 989 stocks

Biological Products, Except Diagnostic Industry

123rd out of 166 stocks

See Top Rated MarketRank™ Stocks Here

TWST stock logo

About Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corp. engages in the development of a proprietary semiconductor-based synthetic DNA manufacturing process. Its products include genes, oligo pools, Next Generation Sequencing (NGS), variant libraries, synthetic controls, antibody discovery, and SARS-CoV-2 Tools. It operates through the following geographical segments: Americas, EMEA, and APAC. The Americas segment consists of the United States of America, Canada, Mexico, and South America. The EMEA segment includes Europe, Middle East, and Africa. The APAC segment consists of Japan, China, South Korea, India, Singapore, Malaysia, and Australia. The company was founded by William Marine Banyai, Emily Marine Leproust, and Bill James Peck on February 4, 2013 and is headquartered in San Francisco, CA.

Receive TWST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

TWST Stock News Headlines

March 23, 2023 | americanbankingnews.com
Twist Bioscience Co. (NASDAQ:TWST) Receives $33.83 Consensus PT from Brokerages
March 10, 2023 | seekingalpha.com
Twist Bioscience: Biopharma And Data Storage Are Underappreciated
March 24, 2023 | Stansberry Research (Ad)
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
March 9, 2023 | finance.yahoo.com
Twist Bioscience Announces Robust Antibody Discovery Services Integrating In Vivo, In Vitro and In Silico Approaches
February 20, 2023 | finance.yahoo.com
Twist Bioscience (TWST) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
February 9, 2023 | wsj.com
FINAL DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in Twist Bioscience Corporation with Losses of $100,000 to Contact the Firm
February 9, 2023 | wsj.com
DEADLINE FRIDAY ALERT: The Schall Law Firm Encourages Investors in Twist Bioscience Corporation with Losses of $100,000 to Contact the Firm
February 9, 2023 | benzinga.com
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Twist Bioscience Corporation (TWST)
March 24, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
February 7, 2023 | wsj.com
CLASS ACTION UPDATE for TWST, AVYA and ENVX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
February 7, 2023 | finance.yahoo.com
Twist Bioscience Announces Technology Early Access of Enhanced Whole Genome Sequencing Solution at AGBT
February 6, 2023 | wsj.com
FRIDAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Twist Bioscience Corporation with Losses of $100,000 to Contact the Firm
February 3, 2023 | markets.businessinsider.com
Twist Bioscience Corp Q1 Loss decreases, beats estimates
February 3, 2023 | msn.com
Twist Bioscience slips after Q1 results as outlook disappoints
February 1, 2023 | wsj.com
Twist Shareholder Notice
January 31, 2023 | finance.yahoo.com
These 2 ‘Oversold’ Stocks Could Be Ready for a Comeback, Say Analysts
January 27, 2023 | benzinga.com
CLASS ACTION UPDATE for AFRM, TWST and ENVX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
January 26, 2023 | wsj.com
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Twist Bioscience Corporation with Losses of $100,000 to Contact the Firm
January 19, 2023 | finance.yahoo.com
Twist Bioscience to Report Fiscal 2023 First Quarter Financial Results on Friday, February 3, 2023
January 13, 2023 | benzinga.com
Twist Bioscience Corporation (TWST) Equity Alert: Contact Robbins LLP for Information About the Class Action Against Twist Bioscience Corporation
January 11, 2023 | wsj.com
Kessler Topaz Meltzer & Check, LLP Has Filed a Securities Fraud Class Action Lawsuit Against Twist Bioscience Corporation
January 10, 2023 | finance.yahoo.com
Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics
January 9, 2023 | benzinga.com
Grabar Law Office Investigates Claims on Behalf of Shareholders of Twist Bioscience Corp. (TWST)
January 9, 2023 | finance.yahoo.com
Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration
January 7, 2023 | apnews.com
Twist Bioscience Corporation (TWST) Equity Notice: Robbins LLP Urges Investors with Significant Losses to Contact the Firm
January 5, 2023 | wsj.com
HAGENS BERMAN Alerts Twist Bioscience (TWST) Investors to Securities Fraud Class Action, Encourages Investors with Losses to Contact Firm's Attorneys
January 2, 2023 | apnews.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates ClaimsOn Behalf of Investors of Twist Bioscience Corporation - TWST
See More Headlines
Receive TWST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat's FREE daily newsletter.

TWST Company Calendar

Last Earnings
2/03/2023
Today
3/24/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
9/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TWST
CUSIP
N/A
CIK
1581280
Web
www.twistbioscience.com
Phone
(800) 719-0671
Fax
N/A
Employees
652
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$33.83
High Stock Price Forecast
$43.00
Low Stock Price Forecast
$29.00
Forecasted Upside/Downside
+111.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.86)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-217,860,000.00
Net Margins
-99.23%
Pretax Margin
-99.20%
Return on Equity
-27.35%
Return on Assets
-22.74%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.46
Quick Ratio
5.93

Sales & Book Value

Annual Sales
$215.79 million
Price / Sales
4.22
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$14.01 per share
Price / Book
1.14

Miscellaneous

Outstanding Shares
56,858,000
Free Float
50,149,000
Market Cap
$911.43 million
Optionable
Not Optionable
Beta
1.22

Key Executives

  • Emily Marine LeproustEmily Marine Leproust
    Chairman & Chief Executive Officer
  • Patrick J. FinnPatrick J. Finn
    President & Chief Operating Officer
  • James M. ThorburnJames M. Thorburn
    Chief Financial Officer
  • Siyuan Chen
    Chief Technology Officer
  • Nimisha Srivastava
    Senior Vice President-Research & Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TWST Stock - Frequently Asked Questions

Should I buy or sell Twist Bioscience stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TWST shares.
View TWST analyst ratings or view top-rated stocks.

What is Twist Bioscience's stock price forecast for 2023?

6 brokers have issued 1-year price targets for Twist Bioscience's shares. Their TWST share price forecasts range from $29.00 to $43.00. On average, they predict the company's stock price to reach $33.83 in the next year. This suggests a possible upside of 111.1% from the stock's current price.
View analysts price targets for TWST or view top-rated stocks among Wall Street analysts.

How have TWST shares performed in 2023?

Twist Bioscience's stock was trading at $23.81 at the beginning of the year. Since then, TWST stock has decreased by 32.7% and is now trading at $16.03.
View the best growth stocks for 2023 here.

When is Twist Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our TWST earnings forecast.

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Co. (NASDAQ:TWST) announced its earnings results on Friday, February, 3rd. The company reported ($0.74) EPS for the quarter, beating analysts' consensus estimates of ($1.09) by $0.35. The business earned $54.20 million during the quarter, compared to the consensus estimate of $54.47 million. Twist Bioscience had a negative trailing twelve-month return on equity of 27.35% and a negative net margin of 99.23%. Twist Bioscience's revenue was up 29.0% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.91) earnings per share.

What ETFs hold Twist Bioscience's stock?

ETFs with the largest weight of Twist Bioscience (NASDAQ:TWST) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), iShares Genomics Immunology and Healthcare ETF (IDNA), Global X Telemedicine & Digital Health ETF (EDOC), ROBO Global Healthcare Technology and Innovation ETF (HTEC), ARK Innovation ETF (ARKK), SPDR S&P Biotech ETF (XBI), Putnam BioRevolution ETF (SYNB) and WisdomTree BioRevolution Fund (WDNA).

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience issued an update on its FY 2023 earnings guidance on Monday, February, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $261.00 million-$269.00 million, compared to the consensus revenue estimate of $265.53 million.

What is Emily Leproust's approval rating as Twist Bioscience's CEO?

44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Twist Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

When did Twist Bioscience IPO?

(TWST) raised $75 million in an IPO on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.83%), JPMorgan Chase & Co. (6.85%), Sumitomo Mitsui Trust Holdings Inc. (5.18%), Nikko Asset Management Americas Inc. (5.16%), William Blair Investment Management LLC (3.60%) and Voya Investment Management LLC (2.76%). Insiders that own company stock include Emily M Leproust, Emily M Leproust, James M Thorburn, Jan Johannessen, John P Molloy, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends.

How do I buy shares of Twist Bioscience?

Shares of TWST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $16.03.

How much money does Twist Bioscience make?

Twist Bioscience (NASDAQ:TWST) has a market capitalization of $911.43 million and generates $215.79 million in revenue each year. The company earns $-217,860,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis.

How many employees does Twist Bioscience have?

The company employs 652 workers across the globe.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.twistbioscience.com. The company can be reached via phone at (800) 719-0671 or via email at maeve@argotpartners.com.

This page (NASDAQ:TWST) was last updated on 3/24/2023 by MarketBeat.com Staff